December 13, 2019

Mayo joins forces with Gore to develop ‘a living drug’

By Karl Oestreich

by Jeff Kiger

Following positive clinic trial results, Mayo Clinic lab is combining its stem cell research with a bioabsorbable material to create "a living drug" to help patients heal better. Mayo Clinic and W. L. Gore & Associates Inc., the Newark, Del.-based firm best known for making Gore-Tex, are forming a joint venture called Avobis Bio to develop implantable cell therapies for difficult-to-treat conditions, such as perianal fistulas that afflict patients with Crohn's disease.

Rochester Post-Bulletin Logo

Reach: The Rochester Post-Bulletin is a daily newspaper that serves Rochester, Austin and its surrounding cities. The newspaper has a daily circulation of more than 30,000 and a weekend circulation of more than 36,000.  The Post-Bulletin online has more than 440,000 unique visitors to its website each month.

Additional coverage: Star Tribune, Plastics Today, Mass Device, Delaware Business Times

Context: Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, have formed a joint venture to advance the development of implantable cell therapies to treat debilitating conditions with no cure. Avobis Bio will combine Mayo Clinic's clinical and cell expertise and Gore’s expertise in material science to address some of the most challenging medical issues. 

Avobis Bio will explore the use of mesenchymal stem cells combined with enabling bioabsorbable scaffolds that enhance the effectiveness of the cells in stimulating the body to heal. Mayo Clinic brings a depth of clinical experience and infrastructure to the team, as well as scientific research and development related to cell therapy. This complements Gore’s experience applying material science expertise in developing and commercializing products in the biopharmaceutical and medical device industries.

"Perianal fistulas are truly life-altering for Crohn's patients, and treatment options have eluded gastroenterologists and surgeons for years," says William Faubion Jr., M.D., a Mayo Clinic gastroenterologist who specializes in inflammatory bowel diseases. "We are excited for the opportunity to work with a partner with such distinct expertise and with a shared mission to advance innovative and patient-centric solutions."

You can read more about the joint venture on Mayo Clinic New Network.

Contact: Duska Anastasijevic

Tags: Uncategorized

Contact Us · Privacy Policy